https://www.selleckchem.com/products/sc144.html
Five discontinued treatment early due to toxicity, and 16 discontinued due to progressive disease. The response rate (RR) for all patients was 39%, but only 33% of these responses are ongoing. Median progression-free survival (PFS) for patients who completed the six-month therapy was 12 months (range, two to 44 months), and median overall survival (OS) has not yet been reached.Conclusions Although RR is comparable to published data, the response duration is shorter. Based on our results, limiting treatment to only six months may increase
Curtir
Comentario
Compartilhar
